The 2025 European Society of Retina Specialists (EURETINA 2025) Congress in Paris was held grandly. Robotrak Technology Co., Ltd. making its European debut with three products, which has drawn significant interest from the global ophthalmology community.

Showcase Pioneering Innovation Devices through Live Demonstrations

✔ Mona - The first commercialized adaptive optics scanning laser ophthalmoscope(AOSLO), cellular-level multi-modal ophthalmic diagnostic imaging system.

✔ Aglaia 577 - Intelligent navigated laser system for real-time eye tracking targeted laser therapy.

✔ Saris - Multi-modal ophthalmic imaging system designed for animals, an non-invasive in-vivo imaging platform research in ophthalmology and interdisciplinary fields.

These products generated an enthusiastic response on-site, with distributors around the world actively engaging in partnership discussions, sparking a significant acceleration in the company's global market expansion.

Dr. Hui Zhang Joins Robotrak to Advance Global Vision

Robotrak welcomed international ophthalmic pathology expert Dr. Hui Zhang to its team as Chief Medical Officer during the event. Dr. Hui Zhang is a seasoned professional with over 40 years of experience spanning clinical ophthalmology, scientific research, and global drug development. With a clinical foundation from West China University and a PhD from Sweden's Lund University, his career at Astra Zeneca and Novo Nordisk cemented his expertise in translational science. 

Now, as Chief Medical Officer at Robotrak Technologies, she integrates clinical insight with scientific discipline to accelerate breakthrough ophthalmic technologies.

First European MONA AOSLO Installation

Shortly after the exhibition, MONA AOSLO took a critical step into the European market—the Mona system completed its first European installation at the Quinze-Vingts National Ophthalmology Hospital in France, marking its official entry into the European market.

As a leading European center for ophthalmic research and treatment, it focuses on visual sciences, disease management, and innovative technology development. The institute has contributed numerous textbook-altering discoveries concerning retinal structure and pathology.

After a detailed review of Mona's imaging operation and output quality, Professor Michel Paques, Ophthalmologist and Medical Director of the hospital, expressed strong approval: "This device will be well-received relatively conservative ophthalmologists. Its ability to rapidly capture high-quality images of fundus cellular morphology and vascular status provides exceptionally accurate information. The design truly considers the practical needs of clinical ophthalmic practice."